Patent: 9,951,042
✉ Email this page to a colleague
Summary for Patent: 9,951,042
| Title: | Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl] pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid |
| Abstract: | The invention relates to a polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene)sulfonyl]pyridin-3-yl}methyl)-2-methyli- ndol-1-yl]-acetic acid which has higher solubility than other forms and is therefore useful for preparing stable pharmaceutical formulations. |
| Inventor(s): | Hilfiker; Rolf (Kaiseraugst, CH), Grosse-Sender; Katja (Kaiseraugst, CH) |
| Assignee: | ATOPIX THERAPEUTICS LIMITED (London, GB) |
| Application Number: | 15/308,290 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,951,042
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | For Injection | 103770 | 06/19/1998 | ⤷ Try a Trial | 2034-05-02 |
| Swedish Orphan Biovitrum Ab (publ) | SYNAGIS | palivizumab | Injection | 103770 | 07/23/2004 | ⤷ Try a Trial | 2034-05-02 |
| Jubilant Hollisterstier Llc | N/A | positive skin test control-histamine | Injection | 103891 | 03/13/1924 | ⤷ Try a Trial | 2034-05-02 |
| Genentech, Inc. | XOLAIR | omalizumab | For Injection | 103976 | 06/20/2003 | ⤷ Try a Trial | 2034-05-02 |
| Genentech, Inc. | XOLAIR | omalizumab | Injection | 103976 | 09/28/2018 | ⤷ Try a Trial | 2034-05-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
